| Date | Title | Description |
| 10.01.2022 | Vineti introduces new PTM® Integration Suite: purpose-built connectivity and interoperability for cell and gene therapies | New PTM® Integration Suite brings a purpose-built integration solution to highly complex, distributed cell and gene therapy workflows.
Focused on secure interoperability for patient-related data, Vineti’s integration solution provides top-t... |
| 12.11.2021 | Cardinal Health : Balancing the Needs of Today with the Opportunities of Tomorrow | Balancing the Needs of Today with the Opportunities of Tomorrow
11/10/2021
By Heidi Hunter, President, Cardinal Health Specialty Solutions at Cardinal Health
Lately, I've been talking with colleagues about how to find the balance between fo... |
| 23.07.2021 | Meet Michelle Snyder, partner at McKesson Ventures | McKesson Ventures is the strategic venture arm of healthcare company McKesson Corporation
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed!
While there ar... |
| 20.04.2021 | McKesson Ventures highlights investment priorities amidst a trail of successful exits | Before she became a partner with McKesson Ventures, Michelle Snyder spent many years building operational experience in digital health at companies such as Epocrates, which became the proving ground for the management teams of future digita... |
| 18.11.2020 | Vineti, Inc. announced that it has received $68.415625 million in funding from a group of investors | On November 18, 2020, Vineti, Inc. closed the transaction. The company has amended the terms of the transaction and received $415,625 in its fourth tranche closing bringing the total funds raised in the transaction to $68,415,625. The trans... |
| 17.10.2020 | Vineti Grabs $33M Series C Extension |
SAN FRANCISCO, CA, Vineti announced the closing of a $33 million extension to its Series C financing, led by Cardinal Health.
>> Click here for more funding data on Vineti
>> To export Vineti funding data to PDF and Excel, c... |
| 15.10.2020 | Vineti Raises $33M; Extends Series C Funding to $68M | Vineti, Inc., a San Francisco, CA-based digital platform of record for personalized therapeutics, closed a $33m extension to its Series C financing.
The Series C extension is led by Cardinal Health, with participation from Marc Benioff and ... |
| 13.10.2020 | News briefing: Regeneron/Sanofi post positive PhIII Dupixent data in pediatric asthma; Vineti scores $33M Series C extension | Regeneron and Sanofi revealed positive Phase III data for their blockbuster Dupixent on Tuesday, paving a potential path forward in pediatric asthma.
Dupixent, evaluated in children between ages 6 and 11, met its prima... |
| 09.02.2020 | Personalized Therapeutics Company Vineti Raises $35 Million | Vineti, the leading digital platform of record for personalized therapeutics, announced it raised $35 million in Series C funding
Vineti — the leading digital platform of record for personalized therapeutics — announced it has closed a $35 ... |
| 07.02.2020 | Vineti Completes $33.5M in Series B |
SAN FRANCISCO, CA, Vineti announced the closing of $33.5 million in Series B investment.
>> Click here for more funding data on Vineti
>> To export Vineti funding data to PDF and Excel, click here
Vineti, Inc., the leadin... |
| 06.02.2020 | Vineti raises $35M in Series C round, eyeing service, geographic expansion | The company said the funding would allow it to develop new software products and enhance the ones it already has, which are used for automation, analytics and ensuring chain of identity and custody for cell therapies, which have highly comp... |
| 05.02.2020 | Vineti Closes $35M Series C Funding | Vineti, Inc., a San Francisco, CA-based digital platform of record for personalized therapeutics, closed a $35m Series C funding round.
The round was led by Cardinal Health, with participation from Novartis Pharma AG and Kite, a Gilead Comp... |
| 23.12.2019 | To make advanced therapies, we need to industrialize personalization | What’s the best way to measure the real rate of progress in personalized cell therapies, gene therapies, and other advanced therapies?
I’ve been tracking the ever-growing flow of reports about these therapies in scientific journals and pres... |
| 16.04.2018 | Cell-therapy startup raises $33.5M from Canaan, Bill Maris’s Section 32 and others | Section 32 is the San Diego-based venture capital firm that that Bill Maris, the former CEO of Google Ventures founder. Pellini joined in December while continuing to be the chairman of Foundation Medicine.
It was a quick sell from his pers... |
| 16.04.2018 | Vineti Raises $33.5M to Accelerate Patient Access to Cell and Gene Therapies | Vineti, Inc., a San Francisco, CA-based software automation and analytics platform for cell and gene therapies has raised $33.5 million in Series B funding led by Canaan and DFJ, with participation from GE Ventures, Section 32, Casdin Capit... |
| 16.04.2018 | Vineti Closes $33.5M in Series B Funding | Vineti, Inc., a San Francisco, CA-based software automation and analytics platform for cell and gene therapies, closed a $33.5m in Series B funding.
The round was led by Canaan and DFJ, with participation from GE Ventures, Section 32, Casdi... |
| 25.06.2017 | Vineti Raises $13.75M Series A from GE Ventures | SAN FRANCISCO, June 20, 2017 (GLOBE NEWSWIRE) -- Vineti, a pioneering cell and gene therapy software and analytics company, today announced it has closed its Series A funding round from GE Ventures, Mayo Clinic Ventures and new investors, D... |
| 23.06.2017 | Term Sheet — Friday, June 23 | OPEN MIC, UBER EDITION
After Uber CEO Travis Kalanick was fired, one of the (many, many) takes on the news was that Uber’s business model is a bigger problem than its toxic culture. Here’s one example of this take from the Wall Street Journ... |
| 23.06.2017 | Vineti Lands $13.75M Series A Funding |
SAN FRANCISCO, CA, Pioneering cell and gene therapy software and analytics company, today announced it has closed its Series A funding round.
>> Click here for more funding data on Vineti
>> To export Vineti funding data to ... |
| 22.06.2017 | Vineti Raises $13.75M in Series A Funding | Vineti, a San Francisco, CA-based cell and gene therapy software and analytics company, closed raised $13.75M in Series A funding.
Backers included GE Ventures, Mayo Clinic Ventures and new investors DFJ and LifeForce Capital.
The company i... |
| 20.06.2017 | GE Ventures spin-out Vineti raises $13.75M for complex biomanufacturing | It’s problems like those that led to the creation of Vineti, a cloud-based software platform for advanced cell and gene therapies.
On Tuesday, the second day of the BIO International Convention in San Diego, the San Francisco, California-ba... |
| 20.06.2017 | GE and the Mayo Clinic back software to bring cancer-fighting gene therapies to market | Behind the incredible process of developing targeted gene therapies to fight diseases like cancer lies an incredibly mundane problem that prevents these treatments from getting to patients — paperwork and procedures.
While $5.7 billion was ... |
| 05.08.2016 | Meet Risa Stack, General Manager at GE Ventures | While GE Ventures does invest in external companies, Risa leads the New Business Creation team
There has been a big debate over the last few years over whether the Series A crunch is real or not. What everyone can agree on, though, is that ... |
| - | Cell-therapy startup raises $33.5M from Canaan, Bill Maris’s Section 32 and others | With a platform promising protection against cell-based therapy supply-chain missteps, Vineti has completed a $33.5 million Series B infusion. Along with the funding, led by Canaan Partners and DFJ, Vineti’s getting two new board members: N... |
| - | FierceBiotech: Vineti nets $35M to build out logistics software for personalized treatments | - |
| - | McKesson Ventures highlights investment priorities amidst a trail of successful exits | Before she became a partner with McKesson Ventures, Michelle Snyder spent many years building operational experience in digital health at companies such as Epocrates, which became the proving ground for the management teams of future digita... |
| - | Vineti raises $35M in Series C round, eyeing service, geographic expansion | The two companies that currently market CAR-T cells for cancers are participating in a funding round for a company that makes software for cell and gene therapy firms.
San Francisco-based Vineti said Wednesday that it closed a Series C fund... |
| - | GE Ventures spin-out Vineti raises $13.75M for complex biomanufacturing | For all the complexity of CAR-T autologous transplant technology, Vineti has a simple question to ask: What if the wrong cells are infused back into the patient?
That scenario is not as far-fetched as it sounds and it’s just one of many log... |
| - | Timmerman Report: First buy, then invest - Novartis, Gilead join $35M bet on Vineti's software | - |
